| Literature DB >> 28616986 |
Ozlem Yavas1, Mikael Svedendahl1, Paulina Dobosz1, Vanesa Sanz1, Romain Quidant1,2.
Abstract
Nanophotonics has become a key enabling technology in biomedicine with great promises in early diagnosis and less invasive therapies. In this context, the unique capability of plasmonic noble metal nanoparticles to concentrate light on the nanometer scale has widely contributed to biosensing and enhanced spectroscopy. Recently, high-refractive index dielectric nanostructures featuring low loss resonances have been proposed as a promising alternative to nanoplasmonics, potentially offering better sensing performances along with full compatibility with the microelectronics industry. In this letter we report the first demonstration of biosensing with silicon nanoresonators integrated in state-of-the-art microfluidics. Our lab-on-a-chip platform enables detecting Prostate Specific Antigen (PSA) cancer marker in human serum with a sensitivity that meets clinical needs. These performances are directly compared with its plasmonic counterpart based on gold nanorods. Our work opens new opportunities in the development of future point-of-care devices toward a more personalized healthcare.Entities:
Keywords: Lab-on-chip; all-dielectric nanoresonators; biosensing; cancer; silicon
Year: 2017 PMID: 28616986 DOI: 10.1021/acs.nanolett.7b01518
Source DB: PubMed Journal: Nano Lett ISSN: 1530-6984 Impact factor: 11.189